Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303
      QxMD      Google Scholar   
Citation:
J. Clin. Oncol vol 37 (21) 1790-9
Year:
2019
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Status:
Presented/Published
Citation Status:
ppub
Note:
Previous presentation of the manuscript; American Society of Hematology Annual Meeting, December 2016
Methodological:
No
Biospecimen:
Yes
DataSharing:
No
SDC:
No
Book Volume:
8
Parents:
2569  
Children:
None
Program:
OGC
Primary Committee:
Lymphoma
Sec. Committees:
   
Pharmas:
 
Grants:
U10CA180821, U10CA180882, U10CA180847, U10CA180833, U10CA180799, U10CA180820, U24CA196171  
Corr. Author:
 
Authors:
                                                     
Networks:
ADM402, ADM403, ALLIANCE, ATLANTIC, CAPITAL, CORA, LAPS-IL036, LAPS-MA036, LAPS-MD017, LAPS-MN026, LAPS-MO011, LAPS-NC007, LAPS-NY016, LAPS-OH007, LAPS-WI020, NC002, NY018, PA075, PA121, TN008   
Study
CALGB-50303
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords: